HACKENSACK, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (ADMA), a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today announced it has appointed Lawrence Guiheen to its Board of Directors. With the appointment of Mr. Guiheen, the Board of Directors will consist of seven members.
